The American biotechnology company Amgen $AMGN has released its quarterly profit report, noting an impressive 11% increase in sales. In addition to this financial upturn, Amgen outlined ambitious plans for a key drug candidate aimed at combating obesity. However, the company faced regulatory setbacks as trials for another weight-loss drug were temporarily suspended, leading to some uncertainties in the market.